CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.94−0.05 (-2.27%)
Close on Nov 17, 2026Market cap $422.73MP/E –Yield –
CytomX Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
CytomX Therapeutics's price to sales ratio was 21.1× on Nov 11, 2026, against 4.4× a year earlier. Over the last 5 years it ranged from 0.4× to 33.3×, with a median of 2.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 21.1× | +16.8 |
| 2025 | Dec 31, 2025 | 4.4× | +3.7 |
| 2024 | Dec 31, 2024 | 0.7× | −0.5 |
| 2023 | Dec 29, 2023 | 1.1× | −1.2 |
| 2022 | Dec 30, 2022 | 2.4× | −6.1 |
| 2021 | Dec 31, 2021 | 8.5× | +4.1 |
| 2020 | Dec 31, 2020 | 4.3× | −1.9 |
| 2019 | Dec 31, 2019 | 6.2× | −2.8 |
| 2018 | Dec 31, 2018 | 9.0× | −6.4 |
| 2017 | Dec 29, 2017 | 15.4× | −21.8 |
| 2016 | Dec 30, 2016 | 37.2× | +34.2 |
| 2015 | Dec 31, 2015 | 3.0× | – |
See a number that looks wrong?